Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 73, Issue 5, Pages 871-882
Publisher
BMJ
Online
2013-04-19
DOI
10.1136/annrheumdis-2012-203116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- OP0263 Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis; results of a phase IIA trial
- (2014) F.P. Vanhoutte et al. ANNALS OF THE RHEUMATIC DISEASES
- LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis
- (2014) E. Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis
- (2012) Y Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- The Structural Basis for Control of Eukaryotic Protein Kinases
- (2012) Jane A. Endicott et al. Annual Review of Biochemistry
- Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
- (2012) Patrick Vermersch et al. BMC Neurology
- Therapeutic targeting of c-KIT in cancer
- (2012) Leonie K Ashman et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Selective JAK1 inhibitor and selective Tyk2 inhibitor patents
- (2012) Peter Norman EXPERT OPINION ON THERAPEUTIC PATENTS
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kinase inhibitors: a new class of antirheumatic drugs
- (2012) Vasileios Kyttaris Drug Design Development and Therapy
- Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial
- (2011) R. F. Spiera et al. ANNALS OF THE RHEUMATIC DISEASES
- A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease
- (2011) Dinesh Khanna et al. ARTHRITIS AND RHEUMATISM
- A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
- (2011) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
- (2011) Roy Fleischmann et al. ARTHRITIS AND RHEUMATISM
- Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury
- (2011) Praveen Anand et al. EUROPEAN JOURNAL OF PAIN
- A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis
- (2011) MARK C. GENOVESE et al. JOURNAL OF RHEUMATOLOGY
- Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
- (2011) Yoshiya Tanaka et al. ARTHRITIS CARE & RESEARCH
- Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
- (2011) François Piette et al. Alzheimers Research & Therapy
- Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir
- (2011) Li Xie et al. PLoS Computational Biology
- Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy
- (2010) Hossein A. Ghofrani et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Inhibitors of p38 suppress cytokine production in rheumatoid arthritis synovial membranes: Does variable inhibition of interleukin-6 production limit effectiveness in vivo?
- (2010) Theresa H. Page et al. ARTHRITIS AND RHEUMATISM
- An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents
- (2010) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase
- (2010) Antonio Garrido Montalban et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
- (2010) Michael E. Weinblatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- cAMP-dependent protein kinase: Crystallographic insights into substrate recognition and phosphotransfer
- (2010) Madhusudan et al. PROTEIN SCIENCE
- A Multitude of Kinases—Which are the Best Targets in Treating Rheumatoid Arthritis?
- (2010) Tamsin M. Lindstrom et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics
- (2009) M. Humbert et al. ALLERGY
- Imatinib Treatment for Idiopathic Pulmonary Fibrosis
- (2009) Craig E. Daniels et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy
- (2009) R E Alten et al. ANNALS OF THE RHEUMATIC DISEASES
- "Go upstream, young man": lessons learned from the p38 saga
- (2009) D Hammaker et al. ANNALS OF THE RHEUMATIC DISEASES
- Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis
- (2009) Stanley B. Cohen et al. ARTHRITIS AND RHEUMATISM
- Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies
- (2009) Nemanja Damjanov et al. ARTHRITIS AND RHEUMATISM
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Inhibition of p38: Has the fat lady sung?
- (2009) Mark C. Genovese ARTHRITIS AND RHEUMATISM
- Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment
- (2009) Stanley Cohen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis
- (2009) Mary G. Boy et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Selective p38α Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory Disorders
- (2009) David M. Goldstein et al. JOURNAL OF MEDICINAL CHEMISTRY
- Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
- (2009) Patrice Dubreuil et al. PLoS One
- Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
- (2009) Jacques Tebib et al. ARTHRITIS RESEARCH & THERAPY
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
- (2008) Michael E. Weinblatt et al. ARTHRITIS AND RHEUMATISM
- Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk
- (2008) A. Podolanczuk et al. BLOOD
- Platelet-Derived Growth Factor Signaling Through Ephrin-B2 Regulates Hepatic Vascular Structure and Function
- (2008) David Semela et al. GASTROENTEROLOGY
- The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling
- (2008) Olga Ananieva et al. NATURE IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now